Lumiere Therapeutics Raises Over RMB 100 Million to Advance Epigenetic Editing Therapies
Lumiere Therapeutics has raised more than RMB 100 million (approximately $14 million) in a Pre-A financing round, giving the Chinese gene-editing company fresh capital to push its epigenetic editing programs toward the clinic. The financing was co-led by…
Windward Bio’s WIN378 Delivers Positive Phase 2 Asthma Data as Twice-Yearly Anti-TSLP Antibody Moves Into Phase 3
Windward Bio has reported positive interim Phase 2 results for WIN378, also known as HBM9378 or SKB378, showing sustained improvements in lung function and key inflammatory biomarkers after a single dose in patients with uncontrolled asthma. With a…
AIPher Raises ~RMB 100 Million Angel Round to Build AI-Native Drug Discovery Platform
Chinese AI-driven drug discovery startup AIPher has completed an angel financing round of approximately RMB 100 million (about $14 million+), an unusually large early-stage raise completed just over a month after the company was established. The…
HUTCHMED Licenses KRAS-EGFR ATTC HMPL-A830 to GSK in Deal Worth Up to $1.295 Billion
China-based biopharmaceutical company HUTCHMED has entered into an exclusive global licensing and development agreement with GSK for HMPL-A830, a potentially first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC), in a transaction that could…
Simnova Raises Nearly RMB 400 Million in Series B Financing to Advance CAR-NK and In Vivo CAR-T Platforms
Shanghai-based cell therapy developer Simnova has completed a nearly RMB 400 million (approximately US$55 million) Series B financing round, providing fresh capital to advance its lead off-the-shelf CAR-NK program SNC103 and its emerging in vivo CAR-T…
Ascletis Doses First Participant in Global Phase III Program of Oral GLP-1 Drug ASC30
Ascletis Pharma has dosed the first participant in its global Phase III AURORA clinical program evaluating ASC30, a once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management, launching a roughly 4,600-patient registrational…
HUTCHMED’s Fanregratinib Wins China NMPA Approval for FGFR2+ Intrahepatic Cholangiocarcinoma (ICC)
HUTCHMED has secured conditional approval from China’s National Medical Products Administration (NMPA) for fanregratinib (HMPL-453), providing a new targeted treatment option for patients with FGFR2-altered intrahepatic cholangiocarcinoma (ICC). The NMPA…
BioShanghai Week 2026
BioShanghai Week 2026 (or Shanghai International Biopharma Industry Week) will be held September 17–20, 2026 at Zhangjiang Science Hall, Shanghai. Since its sixth edition, BioShanghai Week has become a iconic platform for biopharmaceutical innovation and…
CBI 2026 – Antibody Drug Development Conference
Bispecific antibody deal volumes continue to hit record highs, as the battlefield for antibody therapeutics rapidly expands from oncology into multi-billion-dollar markets such as autoimmune diseases, chronic conditions, and cardiovascular disorders.…
CBI 2026 – XDC Drug Development Conference
Currently, antibody-drug conjugates (ADCs) have entered a critical phase characterized by intensive clinical advancement and commercialization. Meanwhile, emerging technological platforms such as peptide-drug conjugates (PDCs) and radionuclide-conjugated…